L. A. Paroshyna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L. A. Paroshyna has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- A. M. Yurkovskiy
Gomel State Medical University
3 shared publications - S. L. Achinovich
Gomel Regional Clinical Oncology Center
3 shared publications - N. F. Bakalets
Gomel State Medical University
1 shared publication - N.B. Yanko
Gomel State Medical University
1 shared publication - O.V. Pankratov1 shared publication
Latest Publications
- Open Access
- 10 July 2023
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 20 (2) , 59-64
Optimization of treatment of morphea associated with metabolic syndrome
Objective. To study the efficacy of statins in the treatment of morphea in patients with metabolic syndrome and to study the dynamics of inflammatory markers on the background of atorvastatin use.Materials and methods. Atorvastatin at a dose of 20 mg per day was included in the treatment of patients with morphea asociated with metabolic syndrome. Clinical efficacy was evaluated after 3, 6, and 9–12 months on the basis of the dynamics of the modified localized scleroderma skin severity index mLoSSI, changes of laboratory markers of inflammation (C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha)), which was evaluated in 27 patients.Results. In patients whose treatment complex included atorvastatin, there was a persistent clinical improvement, which was manifested in a more pronounced decrease in the modified severity index of morphea mLoSSI relative to the control group after 6, 9-12 months of taking the drug, a marked decrease in the number of recurrences of the disease. When taking atorvastatin in patients with morphea with concomitant metabolic syndrome, there was a statistically significant decrease in the levels of inflammatory markers: CRP and TNF-alpha (p < 0.05).Conclusion. The use of Atorvastatin at a dose of 20 mg per day in patients with limited scleroderma in combination with metabolic syndrome showed pronounced clinical efficacy, reduced the number of recurrences of the disease. There was a decrease in the levels of proinflammatory markers (CRP, TNF-alpha) when taking atorvastatin in patients with morphea associated with metabolic syndrome. The use of atorvastatin in patients with morphea and concomitant metabolic syndrome is effective in preventing relapses of morphea, reducing its severity.
- 10 July 2023
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 20 (2) , 59-64
Open AccessOptimization of treatment of morphea associated with metabolic syndrome
Objective. To study the efficacy of statins in the treatment of morphea in patients with metabolic syndrome and to study the dynamics of inflammatory markers on the background of atorvastatin use.Materials and methods. Atorvastatin at a dose of 20 mg per day was included in the treatment of patients with morphea asociated with metabolic syndrome. Clinical efficacy was evaluated after 3, 6, and 9–12 months on the basis of the dynamics of the modified localized scleroderma skin severity index mLoSSI, changes of laboratory markers of inflammation (C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha)), which was evaluated in 27 patients.Results. In patients whose treatment complex included atorvastatin, there was a persistent clinical improvement, which was manifested in a more pronounced decrease in the modified severity index of morphea mLoSSI relative to the control group after 6, 9-12 months of taking the drug, a marked decrease in the number of recurrences of the disease. When taking atorvastatin in patients with morphea with concomitant metabolic syndrome, there was a statistically significant decrease in the levels of inflammatory markers: CRP and TNF-alpha (p < 0.05).Conclusion. The use of Atorvastatin at a dose of 20 mg per day in patients with limited scleroderma in combination with metabolic syndrome showed pronounced clinical efficacy, reduced the number of recurrences of the disease. There was a decrease in the levels of proinflammatory markers (CRP, TNF-alpha) when taking atorvastatin in patients with morphea associated with metabolic syndrome. The use of atorvastatin in patients with morphea and concomitant metabolic syndrome is effective in preventing relapses of morphea, reducing its severity.
- 24 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (3)
Rapid progression of cutaneous T-cell lymphoma after coronavirus infection
Two cases of skin T-cell lymphoma were presented. They simulated chronic dermatoses with numerous recurrent skin rashes for several years and were not diagnosed in the early stages. Patients were initially diagnosed with allergic contact dermatitis, irritant contact dermatitis, erythema nodosum, skin sarcoidosis, psoriasis, carbuncle, and chronic ulcerative pyoderma and treated with antihistamines, glucocorticoids, antibiotics, and topical agents. In both cases, in the initial stages, patients had a slowly progressive course of dermatoses with periods of exacerbations and remissions. The rapid progression of diseases with a tendency to the skin process generalization, nodular rashes, and the lack of response to therapy occurred shortly after the coronavirus infection. Patients had skin biopsies followed by a pathological and immunohistochemical examination. The clinical examination, medical history, and pathological pattern confirmed the tumor stage of skin lymphoma. For further management, patients were referred to an oncologist.
- 24 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (3)
Rapid progression of cutaneous T-cell lymphoma after coronavirus infection
Two cases of skin T-cell lymphoma were presented. They simulated chronic dermatoses with numerous recurrent skin rashes for several years and were not diagnosed in the early stages. Patients were initially diagnosed with allergic contact dermatitis, irritant contact dermatitis, erythema nodosum, skin sarcoidosis, psoriasis, carbuncle, and chronic ulcerative pyoderma and treated with antihistamines, glucocorticoids, antibiotics, and topical agents. In both cases, in the initial stages, patients had a slowly progressive course of dermatoses with periods of exacerbations and remissions. The rapid progression of diseases with a tendency to the skin process generalization, nodular rashes, and the lack of response to therapy occurred shortly after the coronavirus infection. Patients had skin biopsies followed by a pathological and immunohistochemical examination. The clinical examination, medical history, and pathological pattern confirmed the tumor stage of skin lymphoma. For further management, patients were referred to an oncologist.
- Open Access
- 30 December 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 18 (4) , 55-60
Psychosomatic symptoms in patients suffering from morphea
Objective. To study the features of psychosomatic pathology in patients with morphea.Materials and methods. We used the Symptom Check List-90 Revised (SCL-90-R) to assess patterns of phychological signs in 95 patients suffering from morphea. The control group included 30 respondents without the skin pathology.Results. The patients with morphea revealed higher values in the Global Severity Index (GSI), Positive Symptom Distress Index (PSDI), Positive Symptoms Total (PST). The group of the patients with morphea showed higher distress levels according to the somatization, obsessive and compulsive disorders, depression, anxiety scales.Conclusion. Patients with morphea have a wider range of psychosomatic symptoms. The prevalent characteristics of psychosomatic changes are somatization, obsessive and compulsive disorders, depression, anxiety.
- 30 December 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 18 (4) , 55-60
Open AccessPsychosomatic symptoms in patients suffering from morphea
Objective. To study the features of psychosomatic pathology in patients with morphea.Materials and methods. We used the Symptom Check List-90 Revised (SCL-90-R) to assess patterns of phychological signs in 95 patients suffering from morphea. The control group included 30 respondents without the skin pathology.Results. The patients with morphea revealed higher values in the Global Severity Index (GSI), Positive Symptom Distress Index (PSDI), Positive Symptoms Total (PST). The group of the patients with morphea showed higher distress levels according to the somatization, obsessive and compulsive disorders, depression, anxiety scales.Conclusion. Patients with morphea have a wider range of psychosomatic symptoms. The prevalent characteristics of psychosomatic changes are somatization, obsessive and compulsive disorders, depression, anxiety.
- Open Access
- 1 October 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 3,p. 137-143
Limited scleroderma: sonographic pattern in the stage of erythema/edema
Objective.To describe the sonopattern of limited scleroderma (LS) in the early stages after the onset of erythema.Materials and methods.The work describes a clinical case of limited plaque scleroderma. The sonographic examination was carried out on an ultrasound scanner using a transducer with operating frequencies of 10–16–18 MHz. Material sampling for the histologic examination of the skin was performed from the area with the most pronounced inflammatory changes under sonographic control.Results.It has been found that increased echogenicity of the dermis, “blurring” of the dermis/hypodermis boundary, increased echogenicity and the “stalactite-like” pattern of subcutaneous fat occur in the frst week of the disease; normalization or a signifcant improvement of the sonopattern is noted by the end of the second week or by the beginning of the third week after the onset of erythema.Conclusion.There is a certain parallelism between the histologic and sonographic patterns, which makes it possible to adequately assess both the activity and the stage of the LS process.
- 1 October 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 3,p. 137-143
Open AccessLimited scleroderma: sonographic pattern in the stage of erythema/edema
Objective.To describe the sonopattern of limited scleroderma (LS) in the early stages after the onset of erythema.Materials and methods.The work describes a clinical case of limited plaque scleroderma. The sonographic examination was carried out on an ultrasound scanner using a transducer with operating frequencies of 10–16–18 MHz. Material sampling for the histologic examination of the skin was performed from the area with the most pronounced inflammatory changes under sonographic control.Results.It has been found that increased echogenicity of the dermis, “blurring” of the dermis/hypodermis boundary, increased echogenicity and the “stalactite-like” pattern of subcutaneous fat occur in the frst week of the disease; normalization or a signifcant improvement of the sonopattern is noted by the end of the second week or by the beginning of the third week after the onset of erythema.Conclusion.There is a certain parallelism between the histologic and sonographic patterns, which makes it possible to adequately assess both the activity and the stage of the LS process.
- Open Access
- 28 June 2020
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 57-63
Comorbid pathology of the cardiovascular system in patients suffering from morphea
Objective: to assess the parameters of echocardiography, structure of cardiovascular pathology in patients suffering from morphea. Material and methods. The echocardiographic data and cardiovascular pathology were studied in 74 patients with morphea. Results. Diastolic dysfunction of the left ventricle was revealed in 37.5 % of the morphea patients, dilatation of the left atrium was found in 10.8% of the patients, pathological regurgitation on the aortic valve - in 21.62 %. 86.5 % of the patients had morphea combined with arterial hypertension. Conclusion: Such comorbid pathologies as arterial hypertension, dilatation of the left atrium, pathological regurgitation on the aortic valve and left ventricular diastolic dysfunction are common for patients with morphea.
- 28 June 2020
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 57-63
Open AccessComorbid pathology of the cardiovascular system in patients suffering from morphea
Objective: to assess the parameters of echocardiography, structure of cardiovascular pathology in patients suffering from morphea. Material and methods. The echocardiographic data and cardiovascular pathology were studied in 74 patients with morphea. Results. Diastolic dysfunction of the left ventricle was revealed in 37.5 % of the morphea patients, dilatation of the left atrium was found in 10.8% of the patients, pathological regurgitation on the aortic valve - in 21.62 %. 86.5 % of the patients had morphea combined with arterial hypertension. Conclusion: Such comorbid pathologies as arterial hypertension, dilatation of the left atrium, pathological regurgitation on the aortic valve and left ventricular diastolic dysfunction are common for patients with morphea.